Astellas' Veoza Approved In Europe For Treatment Of Vasomotor Symptoms Associated With Menopause
11/12 02:54
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said that the European Commission approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms or VMS associated with menopause....